2023 World Conference on Lung Cancer (Posters)-EP13.03. Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era

EP13.03. Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era - PDF(Abstract)

Back to course

Pdf Summary

This document provides a summary of a presentation titled "Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era" at the WCLC 2023 conference. The presentation discusses the use of prophylactic cranial irradiation (PCI) and consolidation thoracic radiation (TRT) in the treatment of ES-SCLC lung cancer.<br /><br />ES-SCLC is a type of lung cancer that accounts for 10-15% of all lung cancers and is usually diagnosed at an advanced stage. The addition of chemo-immunotherapy has not significantly improved the two-year survival rate of ES-SCLC patients. The role of PCI in ES-SCLC treatment is still controversial due to conflicting results from previous studies. Similarly, the use of TRT to improve local control has not been widely adopted, and there is a lack of data regarding TRT in the era of chemo-immunotherapy.<br /><br />The authors conducted a retrospective analysis of ES-SCLC patients who received initial chemotherapy or chemo-immunotherapy at their institution from 2008-2021. The analysis included 163 patients who did not have brain metastasis at initial diagnosis. The study collected demographic information, sites of metastatic disease, and treatment details.<br /><br />The results showed that the most common sites of failure after chemo-immunotherapy were the intrathoracic region, liver, bone, and brain. The addition of PCI and TRT was associated with improved overall survival (OS) and progression-free survival (PFS). The median OS for all patients was 11 months, while patients who received PCI had a median OS of 15 months. Patients who received TRT had a median OS of 14 months. The use of chemo-immunotherapy versus chemotherapy did not affect OS. Additionally, PCI improved PFS, while TRT did not.<br /><br />The authors concluded that their findings suggest a survival benefit with both PCI and TRT in ES-SCLC patients who have responded to chemotherapy or chemo-immunotherapy. However, further trials are needed to evaluate the role of PCI and TRT in combination with chemo-immunotherapy.

Asset Subtitle

Tithi Biswas

Meta Tag

Speaker Tithi Biswas

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

Prophylactic Cranial Irradiation

Consolidation Thoracic Radiation

Extensive Stage Small Cell Lung Cancer

ES-SCLC

Chemo-immunotherapy

WCLC 2023 conference

Local control

Overall survival

Progression-free survival

Chemotherapy